Advertisement
ELAN vs ZTS
Which Stock Would AI Choose? Elanco Animal Health (ELAN) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- ELAN has delivered stronger recent performance, with a year-to-date return of approximately 10% compared to significant declines for ZTS.
- Both companies operate in the animal health sector, focusing on pharmaceuticals and vaccines for pets and livestock, but ELAN has shown more robust revenue growth in recent quarters.
- Analyst sentiment favors ELAN with a Strong Buy consensus, while ZTS faces headwinds including lowered guidance and legal matters.
- ELAN benefits from new product launches and pet health segment expansion, contrasting with ZTS’s exposure to competitive pressures in companion animal markets.
- Relative momentum favors ELAN over the past year, with ELAN up over 69% versus notable underperformance for ZTS.
- Sector exposure is similar, yet ELAN exhibits greater resilience in current market conditions based on observable earnings and guidance trends.
Introduction
This comparison examines ELAN and ZTS, two leading companies in the animal health industry. The analysis highlights differences in business focus, recent stock behavior, and market positioning to assist traders and investors evaluating relative opportunities within the healthcare and consumer staples sectors. It is particularly relevant for those seeking insights into sector peers amid varying growth trajectories and sentiment shifts.
ELAN Overview and Recent Performance
Elanco Animal Health Incorporated develops and markets products for companion animals and livestock, including pharmaceuticals, vaccines, and diagnostics. In recent market activity, ELAN shares have shown resilience, closing near $24.91 as of late July 2026, with a year-to-date gain of about 10%. Strong first-quarter 2026 results featured 15% reported revenue growth, driven by pet health segment expansion, prompting raised full-year guidance. Analyst ratings reflect a Strong Buy consensus, supported by innovation pipeline progress and organic growth in key areas.
ZTS Overview and Recent Performance
Zoetis Inc. specializes in animal health medicines, vaccines, and diagnostics primarily for companion animals and livestock. In recent market activity, ZTS shares have traded near $75.35 as of late July 2026, reflecting broader underperformance with a sharply negative year-to-date return. First-quarter 2026 results showed modest 3% revenue growth, accompanied by revised full-year guidance and ongoing competitive dynamics in pet care. Market sentiment has been influenced by litigation developments and sector pressures, contributing to volatility.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots from hundreds available across the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and performance metrics tailored to current market conditions. Only the most suitable ones, based on backtested results, win rates, and adaptability, earn placement in this section. Users can explore diverse options with statistics on returns, drawdowns, and ticker coverage to inform automated trading approaches. Trending AI Robots
Head-to-Head Comparison
Elanco Animal Health and Zoetis both serve the animal health market but differ in scale and focus, with ZTS historically commanding a larger market position in companion animal products. Recent momentum favors ELAN, which has posted stronger returns and raised guidance on innovation revenue, while ZTS contends with guidance revisions and legal overhangs. Growth drivers for ELAN include new product launches and organic expansion; ZTS faces heightened domestic competition. Risk factors are elevated for ZTS due to valuation compression and litigation, whereas ELAN offers a more favorable risk-reward profile in the current environment. Market sentiment and sector exposure underscore trade-offs in stability versus growth potential.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings momentum, and relative positioning, Tickeron’s AI would likely favor ELAN in the current setup. Stronger recent performance, positive guidance revisions, and analyst support suggest greater stability and catalysts compared to ZTS, though outcomes remain probabilistic and dependent on broader market developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Hold and ZTS is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ELAN’s FA Score shows that 1 FA rating(s) are green whileZTS’s FA Score has 2 green FA rating(s).
- ELAN’s FA Score: 1 green, 4 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ELAN’s TA Score shows that 5 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).
- ELAN’s TA Score: 5 bullish, 5 bearish.
- ZTS’s TA Score: 4 bullish, 5 bearish.
Price Growth
ELAN (@Pharmaceuticals: Generic) experienced а -6.98% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was -1.85% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.18%. For the same industry, the average monthly price growth was +3.17%, and the average quarterly price growth was +27.02%.
Reported Earning Dates
ELAN is expected to report earnings on Nov 10, 2026.
ZTS is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-1.18% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| ELAN | ZTS | ELAN / ZTS | |
| Capitalization | 11.2B | 31.3B | 36% |
| EBITDA | 731M | 4.06B | 18% |
| Gain YTD | -0.530 | -38.779 | 1% |
| P/E Ratio | 374.14 | 12.37 | 3,024% |
| Revenue | 4.89B | 9.53B | 51% |
| Total Cash | 428M | N/A | - |
| Total Debt | 3.99B | 9.24B | 43% |
ELAN | ZTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 17 | |
PRICE GROWTH RATING 1..100 | 60 | 64 | |
P/E GROWTH RATING 1..100 | 1 | 95 | |
SEASONALITY SCORE 1..100 | 50 | 40 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (10) in the Pharmaceuticals Generic industry is significantly better than the same rating for ELAN (89) in the Agricultural Commodities Or Milling industry. This means that ZTS’s stock grew significantly faster than ELAN’s over the last 12 months.
ZTS's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as ELAN (100) in the Agricultural Commodities Or Milling industry. This means that ZTS’s stock grew similarly to ELAN’s over the last 12 months.
ZTS's SMR Rating (17) in the Pharmaceuticals Generic industry is significantly better than the same rating for ELAN (93) in the Agricultural Commodities Or Milling industry. This means that ZTS’s stock grew significantly faster than ELAN’s over the last 12 months.
ELAN's Price Growth Rating (60) in the Agricultural Commodities Or Milling industry is in the same range as ZTS (64) in the Pharmaceuticals Generic industry. This means that ELAN’s stock grew similarly to ZTS’s over the last 12 months.
ELAN's P/E Growth Rating (1) in the Agricultural Commodities Or Milling industry is significantly better than the same rating for ZTS (95) in the Pharmaceuticals Generic industry. This means that ELAN’s stock grew significantly faster than ZTS’s over the last 12 months.
| ELAN | ZTS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | N/A |
| Stochastic ODDS (%) | 2 days ago 60% | 2 days ago 54% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 58% |
| TrendWeek ODDS (%) | 2 days ago 74% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 53% |
| Advances ODDS (%) | 4 days ago 67% | 4 days ago 50% |
| Declines ODDS (%) | 8 days ago 74% | 10 days ago 62% |
| BollingerBands ODDS (%) | 2 days ago 61% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 51% |
Advertisement
ELAN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with PAHC. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then PAHC could also see price increases.
| Ticker / NAME | Correlation To ELAN | 1D Price Change % | ||
|---|---|---|---|---|
| ELAN | 100% | +1.72% | ||
| PAHC - ELAN | 47% Loosely correlated | +0.77% | ||
| ZTS - ELAN | 44% Loosely correlated | +3.13% | ||
| SNDL - ELAN | 39% Loosely correlated | -0.79% | ||
| VTRS - ELAN | 37% Loosely correlated | -0.37% | ||
| AMRX - ELAN | 34% Loosely correlated | -2.21% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with PAHC. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then PAHC could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +3.13% | ||
| PAHC - ZTS | 58% Loosely correlated | +0.77% | ||
| ELAN - ZTS | 42% Loosely correlated | +1.72% | ||
| AMPH - ZTS | 36% Loosely correlated | +1.00% | ||
| SNDL - ZTS | 33% Loosely correlated | -0.79% | ||
| HLN - ZTS | 32% Poorly correlated | N/A | ||
More | ||||